Tumor Type

United Kingdom
Prostate Cancer - Adenocarcinoma
Project Profile
Funding Organizations
United Kingdom: Cancer Research UK
Research Organizations
Research Activities
Publication Policy

1:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
2:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

China: First Hospital of Peking University
Second Military Medical University
Finland: University of Tampere Institute of Biomedical Technology
Hong Kong: Chinese University of Hong Kong
Singapore: Singapore General Hospital
United Kingdom: Barts and London School of Medicine and Dentistry
Institute of Cancer Research
Royal Marsden NHS Foundation Trust
University of Cambridge
University of Liverpool
University of Oxford

The Institute of Cancer Research (ICR) and Royal Marsden NHS Foundation Trust (RMH):
Professor Colin Cooper, DSc, FMedSci
Professor Rosalind Eeles, FRCR; FRCP; PhD

University of Cambridge:
Professor David Neal
Professor Doug Easton MA; DipMedStats; PhD

University of Liverpool:
Professor Chris Foster

Barts and London School of Medicine and Dentistry:
Dr Yong-Jie Lu, PhD

University of Oxford:
Professor Freddie Hamdy

The Dana-Farber Cancer Institute and The Broad Institute:
Dr. Freedman
Dr. Kantoff

University of Tampere:
Professor G. Steven Bova

Second Military Medical University, Shanghai:
Prof. Yongwei Yu
Prof. Hongwei Zhang

First Hospital of Peking University, Beijing:
Dr Tongli Xia

Chinese University of Hong Kong:
Dr Sim Hong Gee Professor Chi-fai Ng

Singapore General Hospital:
Dr John Yuen

Sequencing & Analysis

China: BGI-Shenzhen
United Kingdom: Illumina
Institute of Cancer Research
University of Cambridge
Wellcome Trust Sanger Institute

Wellcome Trust Sanger Institute:
Professor Stratton, FRS
Dr Andy Futreal, PhD

Complementary Studies

Data Storage, Analysis & Management

United Kingdom: Institute of Cancer Research
University of Cambridge
Wellcome Trust Sanger Institute
Project Summary

The incidence of prostate cancer in the UK has doubled in the last 15 years, mainly due to increased use of serum prostate specific antigen (PSA) testing in healthy men. As a result prostate cancer has become the most common cancer in men. Currently 35,000 men are diagnosed with prostate cancer each year and 11,000 men in the UK will die from this disease. .

Prostate cancer is difficult to manage clinically due to a poor current understanding of what dictates its highly variable natural history, and of what underlies the origin of castration-resistant disease. As many as 50-80% of PSA-detected prostate cancers are biologically irrelevant, that is, even without treatment, they would never have caused any symptoms. However, it is not possible to reliable distinguish indolent from potentially aggressive cancers using convention markers such as PSA, Gleason grade and clinical stage. Treatment of the prostate cancer is also complicated by that fact that the disease is often multi-focal, with apparently genetically distinct cancers frequently arising in a single prostate.

Large variations in incidences occur in different populations, although the underlying reasons for these variations remain to be established. Prostate cancer arising in Asian men, particularly in indigenous Chinese nationals has, long been considered to be of lower incidence and phenotypically distinct disease to that occurring in Caucasian or African-American men. Links set up to collect these cancers include those to Prof. Hongwei Zhang (Shanghai), Dr Ng (Hong Kong), and Dr Yong-Jie Lu (Barts Cancer Institute)

This Cancer Research UK funded Prostate Cancer Network (CR-UKPCN) consists of a multidisciplinary team of histopathologists, urologists, molecular biologists, geneticists and experts in genome technology and bioinformatics. We will collect and analyze 30-50 fold coverage whole genome paired-end sequence data from 250 prostate cancers representing the following groups: (i) cancers from men at different risks of progression; (ii) metastatic castration resistant disease; (iii) apparently separate and genetically distinct (multi-focal) cancers arising in a single prostate; (iii) cancer from arising in men from different ethnic groups.

In parallel it is our intention to collect transcriptomic and epigenetic data on cancers entered into this study. Analyses of the combined datasets will inform on our understanding of the molecular basis of the genetic and clinical heterogeneity of prostate cancer and will provide insights into the reasons for variation in incidence in different ethnic groups. The results may suggest etiological causes for cancer development, and help to personalized treatment for men who develop prostate cancer.

Principal Investigator(s)
Professor Colin Cooper (Institute of Cancer Research) (Joint Lead)
Professor Rosalind Eeles (Institute of Cancer Research) (Joint Lead)
Professor Mike Stratton (Wellcome Trust Sanger Institute)
Dr Andy Futreal (Wellcome Trust Sanger Institute)
Professor David Neal (University of Cambridge)
Professor Doug Easton (University of Cambridge)
Professor G. Steven Bova (Institute of Biomedical Technology, University of Tampere, Finland)
Professor Chris Foster (University of Liverpool)

Lead Jurisdiction